Literature DB >> 32915299

Type 1 diabetes outcomes of children born in Israel of Eritrean asylum seekers.

Erella Elkon-Tamir1, Yael Lebenthal2, Irina Laurian1,3, Anna Dorfman1,3, Efrat Chorna1,4, Hagar Interator1,5, Galit Israeli1, Gil Rosen1, Ori Eyal1, Asaf Oren1, Avivit Brener1.   

Abstract

AIMS: Disparities in health outcomes in pediatric type 1 diabetes (T1D) based on race/ethnicity and socioeconomic position (SEP) have been reported. We compared T1D characteristics between Eritrean status-less children living in Israel and native-born Israeli children.
METHODS: This observational study compared 7 Eritrean and 28 Israeli children (< 8 years old at T1D diagnosis) who were diagnosed in a single diabetes center during 2015-2019. Sociodemographic and diabetes-related data from diagnosis until the last clinic visit were retrieved from their medical files.
RESULTS: At diagnosis, the mean age was 4.8 ± 2.2 years, 17 (48.6%) had diabetic ketoacidosis with a mean HbA1c level of 10.5 ± 2.1% (91.3 mmol/mol) and 29 (82.9%) had ≥ 2 pancreatic autoantibodies. The mean T1D duration of follow-up was 2.7 ± 1.4 years. Overall glycemic control during follow-up (> 6 months from diagnosis, mean number of samples 10.6 ± 5.2) was good, with mean, best, and peak HbA1c levels of 7.4 ± 0.8% (57.4 mmol/mol), 6.7 ± 0.7% (49.7 mmol/mol), and 8.1 ± 1.1% (65 mmol/mol), respectively. Thirty-two children (91.4%) used continuous glucose monitoring devices (CGMs), and the mean time from diagnosis to CGM initiation was 10.8 ± 14.1 months. CGM metrics: time CGM active: 95.4 ± 3.8%, mean glucose level: 170.0 ± 27.0 mg/dl (9.4 mmol/L), time-in-range: 56.4 ± 14.7%, time-below-range: 5.5 ± 5.7%, and time-above-range: 38.6 ± 16.1%. Diabetes-related parameters at diagnosis and during follow-up were similar between groups. Eritrean children had significantly lower SEPs (P < 0.001) and parental education levels (P < 0.001). Correlations between SEP and diabetes parameters and SEP and growth parameters were not significant.
CONCLUSIONS: Eritrean status-less children in Israel achieved glycemic targets similar to those of Israeli children, perhaps reflecting uniformity in the standard of care and CGM usage.

Entities:  

Keywords:  CGM usage; Children of asylum seekers; Glycemic control; Socioeconomic position; Type 1 diabetes

Year:  2020        PMID: 32915299     DOI: 10.1007/s00592-020-01597-3

Source DB:  PubMed          Journal:  Acta Diabetol        ISSN: 0940-5429            Impact factor:   4.280


  30 in total

1.  Identification of Emotional Distress Among Asylum Seekers and Migrant Workers by Primary Care Physicians: A Brief Report.

Authors:  Michal Dick; Shmuel Fennig; Ido Lurie
Journal:  Isr J Psychiatry Relat Sci       Date:  2015       Impact factor: 0.481

2.  Socioeconomic Inequality in Metabolic Control Among Children With Type 1 Diabetes: A Nationwide Longitudinal Study of 4,079 Danish Children.

Authors:  Nick F Nielsen; Amanda Gaulke; Tine M Eriksen; Jannet Svensson; Niels Skipper
Journal:  Diabetes Care       Date:  2019-05-23       Impact factor: 19.112

3.  Impaired metabolic control and socio-demographic status in immigrant children at onset of Type 1 diabetes.

Authors:  U Söderström; U Samuelsson; L Sahlqvist; J Åman
Journal:  Diabet Med       Date:  2014-06-19       Impact factor: 4.359

4.  Increased rates of morbidity, mortality, and charges for hospitalized children with public or no health insurance as compared with children with private insurance in Colorado and the United States.

Authors:  James Todd; Carl Armon; Anne Griggs; Steven Poole; Stephen Berman
Journal:  Pediatrics       Date:  2006-08       Impact factor: 7.124

Review 5.  Israel: health and beyond.

Authors:  Karl Skorecki; Richard Horton
Journal:  Lancet       Date:  2017-05-08       Impact factor: 79.321

6.  Type 1 diabetes (T1DM) in children and adolescents of immigrated families in Emilia-Romagna (Italy).

Authors:  Patrizia Banin; Fiorenza Rimondi; Aldo De Togni; Stefano Cantoni; Giovanni Chiari; Lorenzo Iughetti; Silvana Salardi; Stefano Zucchini; Alberto Marsciani; Tosca Suprani; Luis Tarchini; Anna Tozzola; Rossella Xella; Maria Marsella; Vincenzo De Sanctis
Journal:  Acta Biomed       Date:  2010-12

7.  Public health in the emergency department: overcoming barriers to implementation and dissemination.

Authors:  Mary Pat McKay; Federico E Vaca; Craig Field; Karin Rhodes
Journal:  Acad Emerg Med       Date:  2009-11       Impact factor: 3.451

8.  National Swedish study of immigrant children with type 1 diabetes showed impaired metabolic control after three years of treatment.

Authors:  Ulf Söderström; Ulf Samuelsson; Jan Åman
Journal:  Acta Paediatr       Date:  2016-05-27       Impact factor: 2.299

9.  New definition for the partial remission period in children and adolescents with type 1 diabetes.

Authors:  Henrik B Mortensen; Philip Hougaard; Peter Swift; Lars Hansen; Reinhard W Holl; Hilary Hoey; Hilde Bjoerndalen; Carine de Beaufort; Francesco Chiarelli; Thomas Danne; Eugen J Schoenle; Jan Aman
Journal:  Diabetes Care       Date:  2009-05-12       Impact factor: 17.152

Review 10.  International Consensus on Use of Continuous Glucose Monitoring.

Authors:  Thomas Danne; Revital Nimri; Tadej Battelino; Richard M Bergenstal; Kelly L Close; J Hans DeVries; Satish Garg; Lutz Heinemann; Irl Hirsch; Stephanie A Amiel; Roy Beck; Emanuele Bosi; Bruce Buckingham; Claudio Cobelli; Eyal Dassau; Francis J Doyle; Simon Heller; Roman Hovorka; Weiping Jia; Tim Jones; Olga Kordonouri; Boris Kovatchev; Aaron Kowalski; Lori Laffel; David Maahs; Helen R Murphy; Kirsten Nørgaard; Christopher G Parkin; Eric Renard; Banshi Saboo; Mauro Scharf; William V Tamborlane; Stuart A Weinzimer; Moshe Phillip
Journal:  Diabetes Care       Date:  2017-12       Impact factor: 19.112

View more
  1 in total

1.  Technological Ecological Momentary Assessment Tools to Study Type 1 Diabetes in Youth: Viewpoint of Methodologies.

Authors:  Mary Katherine Ray; Alana McMichael; Maria Rivera-Santana; Jacob Noel; Tamara Hershey
Journal:  JMIR Diabetes       Date:  2021-06-03
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.